Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Transplantation × Clear all
NCT00540995 2023-11-30

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

City of Hope Medical Center

Phase 1/2 Terminated
25 enrolled 9 charts
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡